Adam Harvey

Company: Ferring Pharmaceuticals

Job title: Associate Director - Clinical Research, Global Clinical & Translational Sciences

Seminars:

Final Results from PUNCH CD3-OLS, an Open-Label Clinical Trial of REBYOTA (Fecal Microbiota Live-jslm) in Patients with Recurrent C. Difficile Infection 9:30 am

Topline results will be presented from the largest (n=697 treated) single study of REBYOTA Safety and efficacy will be presented for the study population and subgroups of interest (IBD and Immunosuppressed patients) Results provide further evidence that REBYOTA is safe and well tolerated in a variety of patients with recurrent C. diff infectionRead more

day: Conference Day One